表紙
市場調查報告書
商品編碼
915014

圓形脫髮症 (AA) :機會分析與預測

Alopecia Areata: Opportunity Analysis and Forecasts to 2028

出版日期: | 出版商: GlobalData | 英文 90 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供主要7個國家的圓形脫髮症 (AA)的治療藥市場相關調查分析,疾病概要,流行病學,目前治療選項,未滿足需求和機會,研究開發策略,開發平台評估等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因
  • 病理生理學
  • 分類或分期

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 世界、歷史的趨勢
  • 預測手法
  • 圓形脫髮症 (AA)的流行病學預測
  • 討論

第6章 目前治療選項

  • 概要
  • 診斷
  • 治療

第7章 未滿足需求與機會評估

  • 概要
  • 有效藥的缺乏
  • 患者醫囑遵從性
  • 治療指南的不足
  • 藥物的償付可能性

第8章 研究開發 (R&D) 策略

  • 概要
  • 臨床實驗設計

第9章 開發平台評估

  • 概要
  • 創新的初期階段方法

第10章 開發平台評估分析

  • 主要的開發平台藥物臨床基準
  • 主要的開發平台藥物的商業基準
  • 競爭評估
  • 10年預測
    • 美國
    • EU5個國家
    • 日本

第11章 附錄

目錄
Product Code: GDHC101POA

Alopecia areata (AA) is the second most common non-scarring alopecia and there are no clear reasons for the onset of the condition; however, some sources have suggested that it happens as a result of genetic susceptibility from an environmental change. The disease causes hair loss from different areas of the body; however, it usually occurs more on the scalp or the beard regions. It appears as smooth round patches but with the follicular openings retained, where the hair has become shorter and fragmented because of the disease. Hair loss can result in baldness of the whole scalp, which is referred to as alopecia totalis, or loss of hair on the body, which is called alopecia universalis. Both genders are equally affected, with symptoms of AA starting commonly before the age of 30. The condition occurs in at least 20% of patients who have a first-degree relative who suffers from AA.

Key Highlights:

The main driver of the enormous expansion of the AA market will be the significant increase in patient shares towards the JAK inhibitors due to increased efficacy of these therapies.

Another prominent contributor to sales growth will be the increase in treatment rate in all markets accross the 7MM

The major global barrier for the AA market will be the annual cost of therapy for the new pipeline drugs

The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for AA patients with less occurrence of adverse events

Scope:

  • Overview of AA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized AA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AA therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AA market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global AA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AA therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AA therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Alopecia Areata: Executive Summary

  • 2.1. Intense Growth Expected for AA Market Following the Launch of JAK Inhibitors
  • 2.2. Large Companies Set to Dominate the AA Market
  • 2.3. Vast Unmet Needs Exist in the AA Market
  • 2.4. There is Still Scope for Opportunity in AA Despite the Entrance of JAK Inhibitors
  • 2.5. JAK Inhibitors Dominate Sales for AA
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology
  • 4.2. Pathophysiology
  • 4.3. Classification or Staging Systems

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
    • 5.4.1. Sources
    • 5.4.2. Forecast Assumptions and Methods
    • 5.4.3. Forecast Assumptions and Methods - Diagnosed Incident Cases of AA
    • 5.4.4. Forecast Assumptions and Methods - Lifetime Diagnosed Prevalent Cases of AA
    • 5.4.5. Forecast Assumptions and Methods - Diagnosed Incident Cases and Lifetime Diagnosed Prevalent Cases of AA by Severity
  • 5.5. Epidemiological Forecast for AA (2018-2028)
    • 5.5.1. Diagnosed Incident Cases of AA
    • 5.5.2. Age-Specific Diagnosed Incident Cases of AA
    • 5.5.3. Sex-Specific Diagnosed Incident Cases of AA
    • 5.5.4. Diagnosed Incident Cases of AA by Severity
    • 5.5.5. Lifetime Diagnosed Prevalent Cases of AA
    • 5.5.6. Age-Specific Lifetime Diagnosed Prevalent Cases of AA
    • 5.5.7. Sex-Specific Lifetime Diagnosed Prevalent Cases of AA
    • 5.5.8. Lifetime Diagnosed Prevalent Cases of AA by Severity
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of Analysis
    • 5.6.3. Strengths of Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Diagnosis
  • 6.3. Treatment
    • 6.3.1. Topical Treatments
    • 6.3.2. Systemic Treatments

7. Unmet Needs and Opportunity Assessment

  • 7.1. Overview
  • 7.2. Lack of Efficacious Drugs
  • 7.3. Patient Adherence
  • 7.4. Lack of Treatment Guidelines
  • 7.5. Reimbursement Potential for Medications

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. JAK Inhibitors
  • 8.2. Clinical Trial Design
    • 8.2.1. Current Clinical Trial Design

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Innovative Early-Stage Approaches

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top-Line 10-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

List of Tables

  • Table 1: Alopecia Areata: Key Metrics in the 7MM
  • Table 2: Alopecia Areata - Investigational Guidelines Assessment
  • Table 3: Risk Factors and Comorbidities for AA
  • Table 4: Clinical Trial Design for Key AA Products in Late-Stage Development, July 2019
  • Table 5: Innovative Early-Stage Approaches for Alopecia Areata, 2019
  • Table 6: Clinical Benchmark of Key Pipeline Drugs - Alopecia Areata, 2018
  • Table 7: Commercial Benchmark of Key Pipeline Drugs - Alopecia Areata, 2018
  • Table 8: Key Events Impacting Sales for AA, 2018-2028
  • Table 9: AA Market - Global Drivers and Barriers, 2018-2028
  • Table 10: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for AA in 2018 and 2028
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC),,topical immunotherapy
  • Figure 3: Pathogenesis of Alopecia Areata
  • Figure 4: Visuals for Estimating the Percentage of Scalp Hair Loss to Calculate SALT Scores
  • Figure 5: 7MM, Diagnosed Incidence of Alopecia Areata, Both Sexes, All Ages, 2018
  • Figure 6: 7MM, Lifetime Diagnosed Prevalence of Alopecia Areata, Both Sexes, All Ages, 2018
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Alopecia Areata
  • Figure 8: 7MM, Sources Used to Forecast the Lifetime Diagnosed Prevalent Cases of Alopecia Areata
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases and Lifetime Diagnosed Prevalent Cases by Severity of AA
  • Figure 10: 7MM, Diagnosed Incident Cases of AA, Both Sexes, All Ages, 2018
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of AA, Both Sexes, All Ages, 2018
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of AA, All Ages, 2018
  • Figure 13: 7MM, Diagnosed Incident Cases of AA by Severity, Both Sexes, All Ages, 2018
  • Figure 14: 7MM, Lifetime Diagnosed Prevalent Cases of AA, Both Sexes, All Ages, 2018
  • Figure 15: 7MM, Age-Specific Lifetime Diagnosed Prevalent Cases of AA, Both Sexes, All Ages, 2018
  • Figure 16: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of AA, All Ages, 2018
  • Figure 17: 7MM, Lifetime Diagnosed Prevalent Cases of AA by Severity, Both Sexes, All Ages, 2018
  • Figure 18: Treatment Paradigm for Alopecia Areata
  • Figure 19: Unmet Needs and Opportunities in Alopecia Areata
  • Figure 20: Overview of the Development Pipeline in Alopecia Areata
  • Figure 21: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Alopecia Areata in the 7MM During the Forecast Period
  • Figure 22: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, topical immunotherapy
  • Figure 23: Global (7MM) Sales Forecast by Country for AA in 2018 and 2028
  • Figure 24: Global Sales Forecast by Class for AA in 2018 and 2028
  • Figure 25: Sales Forecast by Class for AA in the US in 2018 and 2028